RaQualia Pharma Inc. (JP:4579)
:4579
Want to see JP:4579 full AI Analyst Report?
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥440.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)352.93K
Market Cap
¥17.46B
Enterprise Value¥17.12B
Total Cash (Recent Filing)¥3.24B
Total Debt (Recent Filing)¥2.90B
Price to Earnings (P/E)7.0
Beta0.94
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.56
Shares Outstanding24,458,673
10 Day Avg. Volume795,170
30 Day Avg. Volume352,926
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsGross margins near 80–92% create durable product-level economics for a discovery-focused biotech. High margins give RaQualia operating leverage as revenue scales, helping fund R&D per unit revenue, bolster partner economics, and support long-term margin sustainability.
Revenue Growth And Return To ProfitabilityThe rebound to positive EBIT and net income alongside ~31% revenue growth in 2025 indicates the pipeline is beginning to scale. Sustained top-line momentum and restored profitability improve financing flexibility and credibility with partners over the medium term.
Partner-driven Monetization ModelAn out-licensing and partnering model structurally reduces capital intensity by shifting clinical and commercialization risk to partners and generating upfront, milestone, and royalty streams. This provides non-dilutive funding optionality and aligns incentives for long-term program advancement.
Bears Say
Weak Cash GenerationNegative operating and free cash flow in 2025 signals that accounting profits are not yet converting into cash. Inconsistent cash conversion across cycles increases reliance on partner payments, equity or debt financing, and may pressure runway for ongoing trials and development programs.
Historic Earnings VolatilityA track record of large year-to-year swings and multiple loss years reduces predictability of future earnings and cash needs. Such volatility complicates long-term planning, heightens refinancing risk, and can make it harder to secure favorable partner terms or steady capital at predictable cost.
Rising Leverage And Low ROELeverage rising from near-zero to a debt/equity around 0.42 increases fixed obligations for a small R&D firm, raising financial risk if cash generation remains uneven. Combined with ROE near 4%, the company is currently generating limited returns on shareholder capital, constraining organic funding ability.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥440.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥17.46B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 88 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on May 15, 2026. The company reported -¥8.84 earnings per share for the quarter, missing the consensus estimate of N/A by -¥8.84.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 24,458,673 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of -¥8.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.514%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.